Microbot Medical Inc. has announced the receipt of a non-dilutive grant from the Israel Innovation Authority, amounting to NIS 2.15 million (approximately $630,000). This funding will enhance the company's manufacturing capabilities as it prepares for the commercialization of the LIBERTY® Endovascular Robotic System, pending marketing clearance from the U.S. FDA. The grant, awarded solely to Microbot Medical, recognizes the company's recent achievements and the potential market impact of its single-use, disposable robotic system. Currently, the LIBERTY® System is an investigational device awaiting FDA 510(k) clearance and is not yet available for sale in the U.S.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.